首页> 外文学位 >Measuring Binding Kinetics of Therapeutic Antibodies to Membrane Receptors Using Nanohole Array SPR Biosensors.
【24h】

Measuring Binding Kinetics of Therapeutic Antibodies to Membrane Receptors Using Nanohole Array SPR Biosensors.

机译:使用纳米孔阵列SPR生物传感器测量治疗性抗体与膜受体的结合动力学。

获取原文
获取原文并翻译 | 示例

摘要

In the field of drug discovery, two important metrics of candidate drugs are their binding affinity and kinetics to target receptors. Dr. Moses Rodriguez and his colleagues at the Mayo Clinic have found monoclonal IgM antibodies exhibiting therapeutic effects for multiple sclerosis and amyotrophic lateral sclerosis in animal models, and therefore desired to obtain the kinetic profiles of these antibodies to their targets. Dr. Sang-Hyun Oh's lab at the University of Minnesota specializes in designing and fabricating plasmonic devices, and have developed a nanohole array sensor coated with silicone dioxide which permits formation of cell mimicking supported lipid bilayers. The focus of this dissertation has been to build these devices and develop assays to measure the binding between these antibodies and receptors in cell extracts and supported lipid bilayers. The first antibody to measure was rHIgM22, which binds to myelin membrane. We did not know the receptor, so we used myelin extracts which would include the unknown receptors, and attached these particles to the sensor surface by passive immobilization. To reduce particle size into the sensor detection window, we extruded the particles through pores of known dimensions. After immobilization we measured binding with antibodies. Unfortunately, binding with rHIgM22 was undetectable, but a similar antibody, mouse IgM O4, which also binds to myelin and has a therapeutic effect, did bind consistently and gave KD, apparent = 2.6 +/- 3.6 nM, ka = 2.5 +/- 0.0l x 104 M-1s -1, and kd,slow = 6.6 +/- 0.3 x 10-5 s-1. The second antibody to measure was rHIgM12, which binds to neuronal membranes. We found rHIgM12 binds to the gangliosides GT1b and GD1a, but not GM1. These gangliosides were incorporated into supported lipid bilayers (5 mol %) and binding to the antibodies was measured. Binding of rHIgM12 to GT1b gave KD, apparent = 24.8 +/- 7.9 nM, ka = 2.19 +/- 0.196 x 104 M-1s-1 , and kd,slow = 4.72 +/- 1.15 x 10-4 s-1. Binding of rHIgM12 to GD1a gave KD, apparent = 42.3 +/- 20.6 nM, ka = 1.79 +/- 0.516 x 104 M -1s-1, and kd,slow = 4.43 +/- 1.38 x 10-4 s-1 .
机译:在药物发现领域,候选药物的两个重要指标是它们与靶受体的结合亲和力和动力学。梅奥诊所的Moses Rodriguez博士及其同事发现,单克隆IgM抗体在动物模型中表现出对多发性硬化症和肌萎缩性侧索硬化症的治疗作用,因此希望获得这些抗体针对其靶标的动力学特征。明尼苏达大学的Sang-Hyun Oh博士实验室专门从事等离子设备的设计和制造,并且已经开发出了一种涂有二氧化硅的纳米孔阵列传感器,该传感器可以形成模拟支持脂质双层的细胞。本论文的重点是构建这些装置并开发测定法来测量细胞提取物和支持的脂质双层中这些抗体与受体之间的结合。第一个要测量的抗体是rHIgM22,它与髓磷脂膜结合。我们不知道受体,因此我们使用了髓磷脂提取物,其中包括未知的受体,并通过被动固定将这些颗粒附着到传感器表面。为了将颗粒尺寸减小到传感器检测窗口中,我们将颗粒通过已知尺寸的孔挤出。固定后,我们测量与抗体的结合。不幸的是,无法检测到与rHIgM22的结合,但是类似的抗体,小鼠IgM O4,也结合髓磷脂并具有治疗作用,确实一致地结合并产生KD,表观= 2.6 +/- 3.6 nM,ka = 2.5 +/- 0.0lx 104 M-1s -1和kd,slow = 6.6 +/- 0.3 x 10-5 s-1。第二种要测量的抗体是rHIgM12,它与神经元膜结合。我们发现rHIgM12结合神经节苷脂GT1b和GD1a,但不结合GM1。将这些神经节苷脂掺入支持的脂质双层(5mol%)中,并测量与抗体的结合。 rHIgM12与GT1b的结合得到KD,表观= 24.8 +/- 7.9 nM,ka = 2.19 +/- 0.196 x 104 M-1s-1,kd,slow = 4.72 +/- 1.15 x 10-4 s-1。 rHIgM12与GD1a的结合得到KD,表观= 42.3 +/- 20.6 nM,ka = 1.79 +/- 0.516 x 104 M -1s-1,kd,slow = 4.43 +/- 1.38 x 10-4 s-1。

著录项

  • 作者

    Jordan, Luke.;

  • 作者单位

    University of Minnesota.;

  • 授予单位 University of Minnesota.;
  • 学科 Biomedical engineering.;Immunology.
  • 学位 Ph.D.
  • 年度 2016
  • 页码 113 p.
  • 总页数 113
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:48:38

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号